BioTelemetry (NASDAQ: BEAT) reported Q2 EPS of $0.20, $0.03 better than the analyst estimate of $0.17. Revenue for the quarter came in at $52.7 million versus the consensus estimate of $50.27 million.

GUIDANCE:

BioTelemetry sees Q3 2016 revenue of $210 million, versus the consensus of $202 million.

• adjusted EBITDA guidance to $44 to $46 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.